Status:
COMPLETED
An Open Study of Tipepidine Hibenzate in Adolescent Patients With Depression
Lead Sponsor:
Chiba University
Conditions:
Depression
Adolescent
Eligibility:
All Genders
10-18 years
Phase:
PHASE2
Brief Summary
Accumulating evidence suggests a role of G protein-coupled inwardly-rectifying potassium (GIRK) channel in the pathology of excitement of nerve, and the medicine with the action (like the Tipepidine H...
Eligibility Criteria
Inclusion
- \[Inclusion Criteria\]
- Depressive Episode for ICD-10 criteria.
- Patients are treated with antidepressants (SSRI ; Fluvoxamine, Paroxetine, Sertraline, Escitalopram, SNRI ; Milnacipran, Duloxetine, NaSSa; Mirtazapine), mood stabilizers (Lithium, Sodium Valproate, Carbamazepine, Lamotrigine), atypical antipsychotics (Risperidone, Olanzapine, Quetiapine, Perospirone, Aripiprazole, Blonanserin, Paliperidone) or not treated.
- Patients are stable for 4-weeks for medication.
- \[Exclusion Criteria\]
- Patients with a previous hypersensitivity to Tipepidine Hibenzate.
- Patients treated with typical antipsychotics and antidepressants except inclusion criteria 2. and mood stabilizers except inclusion criteria 2.
- Pregnant or breast-feeding women
Exclusion
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01835847
Start Date
April 1 2013
End Date
March 1 2014
Last Update
May 23 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Psychiatry, Chiba University School of Medicine
Chiba, Chuo-ku, Japan, 260-8670